Skip to main content

Table 5 Prevalence of different known side effects of DAA therapy among the studied group

From: Study the response of Qurevo (ombitasvir, paritaprevir, and ritonavir) in end-stage renal disease patients with hepatitis C virus

Side effects Number Percent
Fatigue/asthenia 44 88.00
Anemia (Hb < 10 g/dl) 42 84.00
GIT upset 10 20.00
Psychiatric (sleep disorder) 8 16.00
Metabolic (decreased appetite) 8 16.00
Respiratory distress 6 12.00
Nervous system (headache/dizziness) 6 12.00
Musculoskeletal (muscle spasms) 4 8.00
Dermatologic (skin reactions/itching) 3 6.00
Hypersensitivity (angioedema) 0 0.00
Teratogenicity/embryo death 0 0.00
Drug interactions 0 0.00
Hepatic decompensation 0 0.00
Others 11 22.00